Loading company profile …

Pricing Privacy Cookies

CALLUNA PHARMA AS

← Back to search

CALLUNA PHARMA AS

Org.nr. 932 255 189 · Private limited company (AS) · OSLO

Analyze

Key figures 2025

Revenue

NOK 36.3m

▲ 35.1%

Operating profit

-NOK 16m

▲ 39.9%

Net profit

-NOK 10.1m

▲ 14.8%

Equity

NOK 1.1bn

▲ 44%

Employees: 10
Revenue per employee: NOK 3.6m
Operating margin: -44%
Age: 3 years

Source: Regnskapsregisteret (Brønnøysundregistrene) · Fetched 27/10/2026, 10:59

Creating the analysis …

Key information

Chief executive: Mark William-Semrau Gaffney

Financial health 2025

Profitability

-1.2%

Not satisfactory

Solidity

83.9%

Very good

Liquidity

Roles

General manager: Mark William-Semrau Gaffney (b. 1976) – General manager
Board: Mark Frederick Altmeyer (b. 1960) – Chair of the board
Susanne Stuffers (b. 1981) – Board member
Farzad Abdi-Dezfuli (b. 1963) – Board member
Marco Boorsma (b. 1974) – Board member
Mark William-Semrau Gaffney (b. 1976) – Board member
Gijs Robert Van Den Brink (b. 1970) – Board member
Auditor: PRICEWATERHOUSECOOPERS AS – Auditor
Accountant: ADVIS AS – Accountant

Person profiles with every company a person has roles in are coming soon.

Source: Enhetsregisteret (Brønnøysundregistrene) · Fetched 27/10/2026, 10:59

People

People with roles in this company, and the other companies they have roles in.

Farzad Abdi-Dezfuli (b. 1963)
Here: Board member
Also has roles in
Gijs Robert Van Den Brink (b. 1970)
Here: Board member
No other roles registered.
Marco Boorsma (b. 1974)
Here: Board member
No other roles registered.
Mark Frederick Altmeyer (b. 1960)
Here: Chair of the board
No other roles registered.
Mark William-Semrau Gaffney (b. 1976)
Here: General manager, Board member
Also has roles in

(b. 1976)

Industry

72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

Address

Gaustadalléen 21, 0349 OSLO

Employees

Founded

1 September 2023

Website

Not registered

Contact details

Not registered

Auditor

PRICEWATERHOUSECOOPERS AS

Accountant

ADVIS AS

Purpose / activity (in Norwegian)

Å investere i farmasøytiske selskaper og virksomheter, herunder å realisere slike investeringer, samt all annen virksomhet knyttet til dette.

More company details

Organisation number: 932 255 189
Legal form: Private limited company (AS) (AS)
Registered in the Central Coordinating Register: 14 October 2023
Sector: Private aksjeselskaper mv.
VAT register: Registered
Register of Business Enterprises: Registered
Latest annual accounts filed: 2025
Business address: Gaustadalléen 21, 0349 OSLO
Postal address: Calluna Pharma AS, c/o Arxx Therapeutics, Gaustadalléen 21, 0349 OSLO
Municipality: OSLO

Source: Enhetsregisteret (Brønnøysundregistrene) · Fetched 27/10/2026, 10:59

2.25

Very good

Accounts

Operating revenue

NOK 36.3m▲ 35.1%

26.9M

2024

36.3M

2025

Operating profit

-NOK 16m▲ 39.9%

−26.6M

2024

−16M

2025

Net profit

-NOK 10.1m▲ 14.8%

−11.9M

2024

−10.1M

2025

Equity

NOK 1.1bn▲ 44%

769.3M

2024

1.1B

2025

Total assets

NOK 1.3bn▲ 54.6%

853.6M

2024

1.3B

2025

Total liabilities

NOK 212.2m▲ 151.7%

84.3M

2024

212.2M

2025

Source: Regnskapsregisteret (Brønnøysundregistrene) · Fetched 27/10/2026, 10:59

ARXX THERAPEUTICS ASBoard member
CALLUNA PHARMA US, INC.General manager

Susanne Stuffers (b. 1981)

Here: Board member

Also has roles in

CALLUNA PHARMA POOLCO ASBoard member
NYKODE THERAPEUTICS ASABoard member
P53 INVEST ASGeneral manager, Board member
UBIQUITY ASGeneral manager, Chair of the board

Companies

No companies are connected to this entity through roles.

Owners (shareholders) are not in the business register but in the Norwegian Tax Administration's shareholder register. Coming later.

People are matched on name and date of birth from the register, never on name alone. Source: Register of roles (Brønnøysundregistrene) · Fetched 25/10/2026, 22:59